Antiangiogenic effect of oral 2-methoxyestradiol on choroidal neovascularization in mice

Experimental Eye Research

Volumn 83, Issue 5, 2006, Pages 1102-1107

  Funakoshi, Taisaku ^a   Birsner, Amy E ^a   D'Amato, Robert J ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

2 methoxyestradiol; age related macular degeneration; antiangiogenesis; choroidal neovascularization; drug; laser; mouse

Indexed keywords

2 METHOXYESTRADIOL;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; IMAGING SYSTEM; LOW LEVEL LASER THERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; CHOROID; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FLUORESCEIN ANGIOGRAPHY; IMAGE PROCESSING, COMPUTER-ASSISTED; LASER COAGULATION; MACULAR DEGENERATION; MALE; MICE; MICE, INBRED C57BL;

EID: 33748684798     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2006.05.016     Document Type: Article

References (26)

1. Chauhan D., Li G., Auclair D., Hideshima T., Podar K., Mitsiades N., Mitsiades C., Chen L.B., Munshi N., Saxena S., and Anderson K.C. 2-methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating heat shock protein-27. Apoptosis 9 (2004) 149-155
2. Chauhan D., Li G., Sattler M., Podar K., Mitsiades C., Mitsiades N., Munshi N., Hideshima T., and Anderson K.C. Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene 22 (2003) 6296-6300
3. D'Amato R.J., Lin C.M., Flynn E., Folkman J., and Hamel E. 2-methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. USA 91 (1994) 3964-3968
4. Dahut W.L., Lakhani N.J., Gulley J.L., Arlen P.M., Kohn E.C., Kotz H., McNally D., Parr A., Nguyen D., Yang S.X., Steinberg S.M., Venitz J., Sparreboom A., and Figg W.D. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol. Ther 5 (2006) 22-27
5. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., and Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368 (1994) 237-239
6. Gokmen-Polar Y., Escuin D., Walls C.D., Soule S.E., Wang Y., Sanders K.L., Lavallee T.M., Wang M., Guenther B.D., Giannakakou P., and Sledge Jr. G.W. Beta-tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res. 65 (2005) 9406-9414
7. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., Feinsod M., and Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351 (2004) 2805-2816
8. Heier J.S., Antoszyk A.N., Pavan P.R., Leff S.R., Rosenfeld P.J., Ciulla T.A., Dreyer R.F., Gentile R.C., Sy J.P., Hantsbarger G., and Shams N. Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter, controlled, multidose study. Ophthalmology 113 (2006) 642 e1-e4
9. Klauber N., Parangi S., Flynn E., Hamel E., and D'Amato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57 (1997) 81-86
10. Lambert H.M., Capone Jr. A., Aaberg T.M., Sternberg Jr. P., Mandell B.A., and Lopez P.F. Surgical excision of subfoveal neovascular membranes in age-related macular degeneration. Am. J. Ophthalmol. 113 (1992) 257-262
11. LaVallee T.M., Zhan X.H., Herbstritt C.J., Kough E.C., Green S.J., and Pribluda V.S. 2-methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res. 62 (2002) 3691-3697
12. LaVallee T.M., Zhan X.H., Johnson M.S., Herbstritt C.J., Swartz G., Williams M.S., Hembrough W.A., Green S.J., and Pribluda V.S. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res. 63 (2003) 468-475
13. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., Willard M.T., Zhong H., Simons J.W., and Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
14. Miller J.W., Walsh A.W., Kramer M., Hasan T., Michaud N., Flotte T.J., Haimovici R., and Gragoudas E.S. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch. Ophthalmol. 113 (1995) 810-818
15. Newsom R.S., McAlister J.C., Saeed M., and McHugh J.D. Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation. Br. J. Ophthalmol. 85 (2001) 173-178
16. Ninomiya Y., Lewis J.M., Hasegawa T., and Tano Y. Retinotomy and foveal translocation for surgical management of subfoveal choroidal neovascular membranes. Am. J. Ophthalmol. 122 (1996) 613-621
17. Poulaki V., Qin W., Joussen A.M., Hurlbut P., Wiegand S.J., Rudge J., Yancopoulos G.D., and Adamis A.P. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and vegf. J. Clin. Invest. 109 (2002) 805-815
18. Pribluda V.S., Gubish Jr. E.R., Lavallee T.M., Treston A., Swartz G.M., and Green S.J. 2-methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 19 (2000) 173-179
19. Reichel E., Berrocal A.M., Ip M., Kroll A.J., Desai V., Duker J.S., and Puliafito C.A. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology 106 (1999) 1908-1914
20. Robinson M.R., Baffi J., Yuan P., Sung C., Byrnes G., Cox T.A., and Csaky K.G. Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization. Exp. Eye Res. 74 (2002) 309-317
21. Schmidt-Erfurth U., Miller J.W., Sickenberg M., Laqua H., Barbazetto I., Gragoudas E.S., Zografos L., Piguet B., Pournaras C.J., Donati G., Lane A.M., Birngruber R., van den Berg H., Strong H.A., Manjuris U., Gray T., Fsadni M., and Bressler N.M. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch. Ophthalmol. 117 (1999) 1177-1187
22. Sibonga J.D., Lotinun S., Evans G.L., Pribluda V.S., Green S.J., and Turner R.T. Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology 144 (2003) 785-792
23. Sica D.A. Angiogenesis inhibitors and hypertension: An emerging issue. J Clin. Oncol. 24 (2006) 1329-1331
24. Turner R.T., and Evans G.L. 2-methoxyestradiol inhibits longitudinal bone growth in normal female rats. Calcif. Tissue Int. 66 (2000) 465-469
25. Yue T.L., Wang X., Louden C.S., Gupta S., Pillarisetti K., Gu J.L., Hart T.K., Lysko P.G., and Feuerstein G.Z. 2-methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol. Pharmacol. 51 (1997) 951-962
26. Zondor S.D., and Medina P.J. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann. Pharmacother. 38 (2004) 1258-1264